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to the total number of screening procedures performed, colono-
scopies increased 60% (20% to 32%; p = 0.01), ﬂexible sig-
moidoscopy decreased 75% (8% to 2%; p = 0.01), barium
enema decreased 50% (2% to 1%; p = 0.01), and FOBT
decreased 6% (70% to 66%). Gastroenterologists performed an
increasingly large proportion of the colonoscopy procedures
(68% in 2000 vs. 73% in 2004). CONCLUSIONS: Colorectal
cancer screening in the private sector increased between 2000
and 2004. During this time, there was a substantial increase in
the use of colonoscopy and a marked decrease in the use of ﬂex-
ible sigmoidoscopy and barium enema. Additional research is
needed to track trends in these procedures and evaluate their
impact on health policy goals, patient outcomes, and system
capacity.
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OBJECTIVES: Epoetin alfa (EPO) and darbepoetin alfa (DARB)
are two erythropoietic stimulating therapies (ESTs) indicated for
the treatment of chemotherapy-induced anemia. This analysis
compared recent dosage patterns and associated drug costs of
EPO and DARB in hospitalized cancer patients. METHODS: An
analysis of electronic inpatient hospital records from the Premier
Perspective Comparative Hospital Database was conducted.
Study subjects were identiﬁed through hospitalizations recorded
between July 2002 and March 2005 from over 500 hospitals
nationwide. Included were patients ≥18 years of age with a
primary admitting diagnosis of cancer who were treated with
EPO or DARB during their hospital stay. Patients who had
received renal dialysis were excluded. To minimize effect of out-
liers, 5% of patients with extreme doses in each group were
excluded from the dosing analysis. Wholesale acquisition costs
in 2005 (EPO: $0.01217/Unit, DARB: $4.36/mcg) were used to
calculate EST costs. RESULTS: A total of 27,804 patients were
identiﬁed (EPO: 24,814, DARB: 2990). Mean age and gender
distribution were comparable between groups (age: EPO 65.3
years, DARB 64.5 years; % women: EPO 53%, DARB 55%).
Mean cumulative dose per inpatient stay was EPO 61,656 ±
50,274 Units and DARB 259 ± 340mcg, corresponding to a dose
only ratio of 238 :1 (Units EPO: mcg DARB). Average treatment
cost was signiﬁcantly lower in the EPO group, compared to
DARB (EPO: $750, DARB: $1129; p < 0.0001). CONCLU-
SION: This analysis utilizing inpatient data demonstrated a dose
only ratio between EPO and DARB of 238 :1 in patients with
cancer. DARB was found to cost 51% more than EPO based on
the cumulative dose administered during hospitalization.
CARDIOVASCULAR
CV1
INCREMENTAL EXPENDITURE OF TREATING HYPERTENSION
IN THE UNITED STATES
Balu S1,Thomas J2
1Abt Associates Inc, Lexington, MA, USA, 2Purdue University, West
Lafayette, IN, USA
OBJECTIVES: The objective of this study was to determine
incremental direct expenditures of treating hypertension in the
U.S. non-institutionalized population. METHODS: Analysis of
2001 Medical Expenditure Panel Survey (MEPS) data, a national
probability sample survey of 33,556 individuals from the civil-
ian non-institutionalized U.S. population was conducted. Hyper-
tensive patients were identiﬁed as those with hypertension based
ICD-9 codes, i.e., 401-xx-405-xx for medical conditions or
medical events, including inpatient visits, outpatient visits, emer-
gency room visits, home-health visits, ofﬁce-based medical
provider visits, and other medical expenses, or patients who self-
reported being diagnosed with hypertension by their physician,
or patients who were prescribed an anti-hypertensive medication
listed in seventh report of the Joint National Committee on Pre-
vention, Detection, Evaluation, and Treatment of Hypertension,
unless there was an indication that the medication was pre-
scribed for a medical condition other than hypertension. Only
individuals 18 years of age or older were included. Incremental
expenditures for treating hypertension were estimated through
least squares regression adjusting for age, gender, race, educa-
tion, and co-morbidities using the D’Hoore version of the Charl-
son co-morbidity index. Sample data were projected to the U.S.
population and 95% conﬁdence limits for estimates were calcu-
lated using the Taylor expansion method. RESULTS: Sample
estimates projected to the population indicated that approxi-
mately 17.4% of individuals aged 18 years and above in the
ambulatory population have hypertension. Total incremental
annual direct expenditures for hypertension patients were esti-
mated to be more than $US 54.0 billion in 2001 after adjusting
for demographics and co-morbidities. Mean incremental annual
direct expenditures for an individual with hypertension was $US
1131. Prescription medicines, inpatient visits, and outpatient
visits constituted more than 90% of overall incremental expen-
ditures. CONCLUSIONS: With incremental direct medical
expenditures estimated at nearly $US55.0 billion, hypertension
expenditures represent a signiﬁcant amount of health care
resource utilization.
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OBJECTIVES: To determine the impact of ventricular arrhyth-
mia on mortality and health care resource utilization in hospi-
talized patients with acute myocardial infarction (AMI).
METHODS: A retrospective cohort study design was used.
Adult patients with primary diagnosis of AMI (ICD-9 code:
410.x1), between July 2003 and June 2004, were identiﬁed from
a large retrospective database of 800 hospitals in the United
States. The AMI patients were further classiﬁed based on sec-
ondary diagnosis of ventricular arrhythmia into three groups:
AMI with sustained ventricular tachycardia (sustained VT)/ven-
tricular ﬁbrillation (VF) (ICD-9 code: 427.4x, 427.5); AMI with
paroxysmal ventricular tachycardia (PVT) (ICD-9 code 427.1);
and AMI without ventricular arrhythmia. Mortality rates, length
of hospital stay and cost were compared between the groups
using chi-square and ANOVA tests. RESULTS: A total of 91,225
patients with primary diagnosis of AMI were identiﬁed, of which
8125 (8.9%) patients had a secondary diagnosis of ventricular
arrhythmia, including sustained VT/VF (N = 3004; 3.3%) and
PVT (N = 5121; 5.6%). A majority of the AMI patients with
ventricular arrhythmia were male (70.2%), caucasian (73.4%)
and ≥65 years (55%). In-hospital mortality rates were higher in
the AMI patients with sustained VT/VF (28.5%) and PVT
(7.9%), than AMI patients without ventricular arrhythmia
(6.2%). The average hospital length of stay was signiﬁcantly
higher (p < 0.001) in AMI patients with sustained VT/VF (8.0 ±
